As a result, according its intrinsic properties, nimotuzumab would only recognize tissues with an aberrant EGFR overexpression like tumors or respiratory cells affected by infections leading to diffuse alveolar degeneration like in COVID-19 (32). This evidence concerns the gene EGFR and COVID-19.